Real World Experience
with EYLEA® (aflibercept) 8 mg
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
Explore the real-world experiences of UK clinicians implementing EYLEA® (aflibercept) 8 mg, highlighting its potential to address unmet needs in the treatment of nAMD, DMO and RVO.
Latest UK Audits of EYLEA 8 mg in nAMD
These UK audit videos highlight the real life usage of EYLEA 8 mg within leading ophthalmology clinics. Watch these videos to learn more about the impact of EYLEA 8 mg on patient care and clinical practice.
In this video,
- Duration: ~6 minutes
- 26 treatment-naïve eyes
- nAMD
Prescribing information for EYLEA® (aflibercept)
Confidence in Every Dose: Real-World Outcomes with EYLEA 8 mg
Explore our 'Confidence in Every Dose' webinar through
In this video,
- Duration: ~5 minutes
- Treatment-naïve patients
- nAMD
Prescribing information for EYLEA® (aflibercept)
International Medical Retina Congress Highlights on EYLEA 8 mg
These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg and highlight key learnings and updates from recent congresses.
In this 5-minute video,
Prescribing information for EYLEA® (aflibercept)
Early real-world experiences with EYLEA 8 mg booklet
- Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust
- Newmedica Eye Health Clinic & Surgical Centre, Grimsby
- Western Eye Hospital, Imperial College Healthcare NHS Trust
DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service. RVO, retinal vein occlusion. VEGF, vascular endothelial growth factor.
Prescribing information for EYLEA® (aflibercept)
PP-EYL-GB-3082 | March 2026